Scholarlink

Objective <p>There is dearth of clinical data from India regarding outcomes of umbilical cord blood transplant (UCBT). This study aimed to analyze the long-term outcomes in children who underwent UCBT at a single Indian center.</p> Methods <p>This retrospective study included patients who underwent UCBT between 2011 and 2024 in a tertiary care center in Northern India. Data on HLA-matching, cell dose, conditioning, engraftment, toxicities and survival outcomes were recorded.</p> Results <p>Out of 20 patients with median (Q1, Q3) age 4 (2, 6) years, 11 had leukemia and 9 had immunodeficiencies or enzymopathies. Majority (90%) received myeloablative-conditioning. Median CD34 + cell dose and total nucleated-cell dose were 3.3 × 10<sup>5</sup>/kg, and 9.6 × 10<sup>7</sup>/kg, respectively, with median (Q1, Q3) time for neutrophil engraftment of 28.5 (23, 36) days. The disease-free-survival (DFS) was 40.3, 77.8 and 10.2% in the overall cohort, benign- and malignant-cohorts, respectively, with 20% transplant-related mortality.</p> Conclusions <p>Umbilical cord blood-transplant showed good outcomes in non-malignant diseases in the absence of matched-related-donors, while, for malignancies, outcomes were suboptimal compared to global figures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcome of Unrelated Umbilical Cord Blood Transplantation in India: A Less Explored Horizon

  • 期刊论文

  • 发表日期：

    2025年7月29日

查看全文
  • Debabrata Mohapatra,
  • Sameer Bakhshi,
  • Ranjit Kumar Sahoo,
  • Atul Batra,
  • Surender K. Sharawat,
  • Deepam Pushpam

摘要

Objective

There is dearth of clinical data from India regarding outcomes of umbilical cord blood transplant (UCBT). This study aimed to analyze the long-term outcomes in children who underwent UCBT at a single Indian center.

Methods

This retrospective study included patients who underwent UCBT between 2011 and 2024 in a tertiary care center in Northern India. Data on HLA-matching, cell dose, conditioning, engraftment, toxicities and survival outcomes were recorded.

Results

Out of 20 patients with median (Q1, Q3) age 4 (2, 6) years, 11 had leukemia and 9 had immunodeficiencies or enzymopathies. Majority (90%) received myeloablative-conditioning. Median CD34 + cell dose and total nucleated-cell dose were 3.3 × 105/kg, and 9.6 × 107/kg, respectively, with median (Q1, Q3) time for neutrophil engraftment of 28.5 (23, 36) days. The disease-free-survival (DFS) was 40.3, 77.8 and 10.2% in the overall cohort, benign- and malignant-cohorts, respectively, with 20% transplant-related mortality.

Conclusions

Umbilical cord blood-transplant showed good outcomes in non-malignant diseases in the absence of matched-related-donors, while, for malignancies, outcomes were suboptimal compared to global figures.